184 related articles for article (PubMed ID: 38515954)
1. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract][Full Text] [Related]
2. Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
Fan Z; Gong Y; Huang Q; Yang C; Cheng H; Jin K; Fan K; Ni Q; Yu X; Luo G; Liu C
Pancreas; 2020 Jul; 49(6):751-756. PubMed ID: 32541629
[TBL] [Abstract][Full Text] [Related]
3. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
4. A single-center experience with pancreatic cystic neuroendocrine tumors.
Khalil A; Ewald J; Marchese U; Autret A; Garnier J; Niccoli P; Piana G; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2020 Aug; 18(1):208. PubMed ID: 32799893
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Taherifard E; Bakhtiar M; Mahnoor M; Ahmed R; Cavalcante L; Zhang J; Saeed A
BMC Cancer; 2024 Feb; 24(1):192. PubMed ID: 38347461
[TBL] [Abstract][Full Text] [Related]
6. Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors: Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case.
Hu HF; Hu YH; Xu XW; Ye Z; Lou X; Zhang WH; Chen XM; Zhang Y; Yu XJ; Gao HL; Xu JY; Ji SR
Pancreas; 2022 Nov-Dec 01; 51(10):1404-1410. PubMed ID: 37099786
[TBL] [Abstract][Full Text] [Related]
7. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract][Full Text] [Related]
8. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.
Krogh S; Grønbæk H; Knudsen AR; Kissmeyer-Nielsen P; Hummelshøj NE; Dam G
Front Endocrinol (Lausanne); 2022; 13():925632. PubMed ID: 35837305
[TBL] [Abstract][Full Text] [Related]
9. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
[TBL] [Abstract][Full Text] [Related]
10. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis.
Cen D; Chen J; Li Z; Zhao J; Cai X
PLoS One; 2017; 12(11):e0187588. PubMed ID: 29136022
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.
Saleh Z; Moccia MC; Ladd Z; Joneja U; Li Y; Spitz F; Hong YK; Gao T
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279330
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
14. Determination and characterization of molecular heterogeneity and precision medicine strategies of patients with pancreatic cancer and pancreatic neuroendocrine tumor based on oxidative stress and mitochondrial dysfunction-related genes.
Cui Y; Yuan Q; Chen J; Jiang J; Guan H; Zhu R; Li N; Liu W; Wang C
Front Endocrinol (Lausanne); 2023; 14():1127441. PubMed ID: 37223030
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma.
Kim JH; Eun HW; Kim YJ; Lee JM; Han JK; Choi BI
Eur Radiol; 2016 May; 26(5):1338-47. PubMed ID: 26253257
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CT characteristics in GEP-NET: A systematic review.
van der Velden DL; Staal FCR; Aalbersberg EA; Castagnoli F; Wilthagen E; Beets-Tan RGH
Crit Rev Oncol Hematol; 2022 Jul; 175():103713. PubMed ID: 35598829
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Syndrome Is Associated with Impaired Survival after Surgery for Pancreatic Neuroendocrine Tumors.
Awwad F; Ozga AK; Amin T; Schlueter C; Kailani S; Perez D; Wolter S; Sauter G; Izbicki J; Lohse AW; Schrader J
Neuroendocrinology; 2022; 112(12):1225-1236. PubMed ID: 35354139
[TBL] [Abstract][Full Text] [Related]
18. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Regional Lymph Node Station in Pancreatic Neuroendocrine Tumor.
Takagi K; Umeda Y; Yoshida R; Yoshida K; Fuji T; Kumano K; Yasui K; Yagi T; Fujiwara T
Anticancer Res; 2022 May; 42(5):2797-2801. PubMed ID: 35489738
[TBL] [Abstract][Full Text] [Related]
20. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
